News articles about ANI Pharmaceuticals (NASDAQ:ANIP) have trended somewhat negative recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. ANI Pharmaceuticals earned a media sentiment score of -0.02 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 46.5610760192307 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Several research analysts have recently commented on the company. Zacks Investment Research raised ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a research report on Tuesday, November 7th. ValuEngine downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, December 20th. Canaccord Genuity restated a “buy” rating and set a $66.00 target price (up from $60.00) on shares of ANI Pharmaceuticals in a research note on Monday, October 16th. BidaskClub downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 21st. Finally, TheStreet upgraded ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Thursday, November 16th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. ANI Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $71.00.

ANI Pharmaceuticals (NASDAQ ANIP) opened at $69.94 on Monday. ANI Pharmaceuticals has a one year low of $42.23 and a one year high of $74.70. The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.39 and a current ratio of 3.45. The firm has a market capitalization of $815.01, a price-to-earnings ratio of 109.28 and a beta of 2.90.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.12. ANI Pharmaceuticals had a return on equity of 22.40% and a net margin of 4.45%. The firm had revenue of $48.16 million for the quarter, compared to the consensus estimate of $48.12 million. During the same period in the previous year, the business earned $1.09 EPS. The firm’s revenue for the quarter was up 25.0% on a year-over-year basis. analysts predict that ANI Pharmaceuticals will post 3.59 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with's FREE daily email newsletter.